2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Cytoskeleton
  4. Kinesin
  5. Kinesin Inhibitor

Kinesin Inhibitor

Kinesin Isoform Comparison

Kinesin Inhibitors (76):

Cat. No. Product Name Effect Purity
  • HY-132840
    Sovilnesib
    		Inhibitor 99.89%
    Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC50 value of 0.071 μM. Sovilnesib can be used for the research of cancer.
  • HY-50759
    Ispinesib
    		Inhibitor 99.62%
    Ispinesib is a specific inhibitor of kinesin spindle protein (KSP), with a Ki app of 1.7 nM.
  • HY-101071A
    Monastrol
    		Inhibitor 99.89%
    Monastrol is a potent and cell-permeable inhibitor of the mitotic kinesin Eg5 with an IC50 value of 14 μM.
  • HY-10299
    GSK-923295
    		Inhibitor 99.82%
    GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with Ki of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively.
  • HY-15187
    Filanesib
    		Inhibitor 98.23%
    Filanesib (ARRY-520) is a selective and noncompetitive kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib induces cell death by apoptosis in vitro. Filanesib has potent anti-proliferative activity.
  • HY-164978
    KIF18A-IN-14
    		Inhibitor
    KIF18A-IN-14 (Compound Example 81) is a KIF18A inhibitor. KIF18A-IN-14 is available in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit OVCAR-3 cells viability with IC50s of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be used in tumor (e.g. colon, breast, lung) studies.
  • HY-170850
    MKLP2-IN-1
    		Inhibitor
    MKLP2-IN-1 (compound 12a) is an inhibitor of MKLP2 with good oral bioavailability. MKLP2-IN-1 inhibits the microtubule-stimulated ATPase activity of recombinant MKLP2 in vitro and suppresses tumor growth in a mouse Calu-6 lung cancer model.
  • HY-12241
    AZ82
    		Inhibitor 99.31%
    AZ82 is a selective kinesin-like protein KIFC1 (HSET/KIFC1) inhibitor, with a Ki of 43 nM and an IC50 of 300 nM for KIFC1.
  • HY-W011102
    S-Trityl-L-cysteine
    		Inhibitor 99.10%
    S-Trityl-L-cysteine (NSC 83265) is a selective and allosteric kinesin Eg5 inhibitor with an IC50 of 1 μM for the inhibition of basal ATPase activity and 140 nM for the microtubule-activated ATPase activity. S-Trityl-L-cysteine has antitumor activities.
  • HY-14846
    Litronesib
    		Inhibitor 99.59%
    Litronesib (LY2523355) is a selective mitosis-specific kinesin Eg5 inhibitor, with antitumor activity.
  • HY-12069
    SB-743921 hydrochloride
    		Inhibitor 99.87%
    SB-743921 hydrochloride is a potent inhibitor of the mitotic kinesin KSP (Eg5), with a Ki of 0.1 nM.
  • HY-101770
    BTB-1
    		Inhibitor 99.75%
    BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM.
  • HY-153065
    KIF18A-IN-6
    		Inhibitor 98.56%
    KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity.
  • HY-101298
    Paprotrain
    		Inhibitor 99.87%
    Paprotrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC50 of 1.35 μM and a Ki of 3.36 μM and shows a moderate inhibition activity on DYRK1A with an IC50 of 5.5 μM.
  • HY-19944
    Dimethylenastron
    		Inhibitor 98.07%
    Dimethylenastron is a potent kinesin Eg5 inhibitor, with an IC50 of 200 nM.
  • HY-15857
    CW-069
    		Inhibitor 99.37%
    CW-069 is an allosteric inhibitor of microtubule motor protein HSET with an IC50 of 75 μM.
  • HY-15000
    EMD534085
    		Inhibitor 99.55%
    EMD534085 is a potent and selective inhibitor of the mitotic kinesin-5 with an IC50 of 8 nM.
  • HY-144894
    AM-5308
    		Inhibitor 99.26%
    AM-5308 is a potent kinesin KIF18A inhibitor (WO2021211549A1, C13).
  • HY-15948
    Kif15-IN-1
    		Inhibitor 99.63%
    Kif15-IN-1 is an inhibitor of the mitotic Kinesin family member 15 (Kif15), and is used for the research of cellular proliferative diseases.
  • HY-122247
    PVZB1194
    		Inhibitor 99.90%
    PVZB1194 is a biphenyl-type inhibitor of Kinesin-5 ATPase activity that binds to the α4/α6 site of the motor domain in a nucleotide competitive manner. PVZB1194 has an IC50 of 0.12 μM for KSP ATPase. PVZB1194 induces mitotic arrest with the formation of a monopolar spindle, and inhibits HeLa cells proliferatio (IC50: 5.5 μM). PVZB1194 can be used in the study of tumors.